2012, Number 1
<< Back Next >>
Rev Esp Med Quir 2012; 17 (1)
Identification of kidney disease in apparently healthy relatives of patients undergoing hemodialysis
Méndez DA, González CRM, Mendoza GK
Language: Spanish
References: 105
Page: 29-33
PDF size: 183.54 Kb.
ABSTRACT
Background: Magnitude of chronic kidney disease has led to identify high frequency of renal dysfunction in early stages, when the course is asymptomatic and even more in apparently healthy subjects. Relatives of patients in hemodialysis have environmental conditions, socioeconomic, dietary habits and lifestyle similar to the patient, which make them vulnerable to kidney disease without knowing it.
Objective: To identify renal function in apparently healthy relatives of patients on hemodialysis.
Material and methods: We performed a prospective, open and cross study during 6 months (October 2010 to March 2011), including apparently healthy subjects. Data collected through an initial interview and a clinical evaluation, were: weight, height, blood pressure, albuminuria, blood glucose and serum creatinine.
Results: We included 111 subjects, 73 women (66%) and 38 male (34%), mean age 40 years (limits: 18-78). Average blood glucose values were 127.5 mg/dL (limits: 86-241); systolic blood pressure was 106.8 mmHg (limits: 90-170) and diastolic was 70.6 mmHg (limits: 60-110); serum creatinine 0.8 mg/dL (limits: 0.5-1.5); glomerular filtration rate was 121.8 mL/min/1.73 m
2 bodily surface (limits: 76.5-198), albuminuria 15.6 mg/day (0-530), and body mass index of 30.1 (limits: 21-42).
Conclusions: The studied population suffered metabolic and kidney asymptomatic alterations with increased frequency.
REFERENCES
Nahas A, Bello A. Chronic kidney disease: the global challenge.
Foster MC, Hwang SJ, Larson MG, et al. The Framingham
heart study. Am J Kidney Dis 2008;52(1):39-48.
Martínez CA, Martín de Francisco AL, Górriz JL, Alcázar
LO. Estrategias en salud renal: un proyecto de la Sociedad
Española de Nefrología. Nefrología 2009;29(3):185-192.
Bakris G, Williams M, Dworking L, et al. Preserving renal
function in adults with hypertension and diabetes: a consensus
approach. Am J Kidney Dis 2000;35:646-661.
Martín de Francisco AL, Aguilera L, Fuster V. Enfermedad
cardiovascular, enfermedad renal y otras enfermedades
crónicas. Es necesaria una intervención más temprana en
la enfermedad renal crónica. Nefrología 2009;29(1):6-9.
Inserra F, De la Llave G, Dorado E, Castagna R, Marelli C.
Estudio de factores de riesgo y enfermedad renal de familiares
en primer grado de pacientes en diálisis. Nefrología
Latinoamericana 2009;13(1):235,S372.
Amato D, Álvarez-Aguilar C, Castañeda LR, et al. Prevalence
of chronic kidney disease in an urban Mexican population.
Kidney Int 2005;68(Suppl 97):S11-S17.
Méndez DA. Prevención del daño, manejo de la enfermedad
renal crónica en el primer nivel de atención médica. Atem
Rosas PM, Lara EA, Pastelín HG. Re-encuesta Nacional
de Hipertensión Arterial (RENAHTHA): Consolidación
Mexicana de los Factores de Riesgo Cardiovascular.
Cohorte Nacional de Seguimiento. Arch Cardiol Mex
Saracho RR, Martínez FI, Amoroto E, et al. Prevalencia de
enfermedad renal crónica (IRC) estadio 3 en la población
general. Nefrología Latinoamericana 2009;13(1):168.S217.
Méndez-Durán A, Méndez-Bueno JF, Tapia-Yáñez T,
Muñoz-Montes A, Aguilar-Sánchez L. Epidemiología de la
insuficiencia renal crónica en México. Diálisis y Trasplante
Clinical guidelines on the identification, evaluation and
treatment of overweight and obesity in adults. National Heart
Lung and Blood Institute, 1998.
The seven report of the Joint National Committee Report
on prevention, detection, evaluation and treatment of high
blood pressure 2003. JAMA 2003;289:2560-2572.
Diagnosis and classification of diabetes mellitus. American
Diabetes Association. Diabetes Care 2009;32(Suppl 1).
Diabetic Nephropathy. American Diabetes Association.
Diabetes Care 2003;26(Suppl 1):S94.
KDOQI Guidelines 2000. National Kidney Foundation. Am
J Kidney Dis 2002;39(Suppl 1):2.
Rossi MCE. Identifying patients with type 2 diabetes at high
risk of microalbuminuria: results of the DEMAND (Developing
Education on Microalbuminuria for awareness of renal
and cardiovascular risk in diabetes) Study. Nephrol Dial
Transplant 2008;23:1278-1284.
Bakris GL. Microalbuminuria: what is it? Why is it important?
What should be done about it? J Clin Hypertens
Weir MR. Microalbuminuria and cardiovascular disease. Clin
J Am Soc Nephrol 2007;2:581-590.
Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A,
Pastelin-Hernández G. Grupo ENSA 2000. Hipertensión
arterial en México: resultados de la Encuesta Nacional de
Salud (ENSA) 2000. Arch Cardiol Mex 2002;72(1):71-84.
Praga M, Hernández E, Morales E, et al. Clinical features
and long term outcome of obesity associated focal
segmental glomeruloesclerosis. Nephrol Dial Transplant
Chen J, Muntner P, Lee HL, et al. The metabolic syndrome
and chronic kidney disease in US Adults. Ann Intern Med
Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HJ.
Obesidad y daño a órgano blanco: el riñón. Int J Obes
Aldhahi W, Hamdy O. Adipocinas, inflamación y endotelio
en la diabetes. Curr Diab Rep 2004;3:22-27.
Iglesias P, Diez J. Adipose tissue in renal disease: clinical
significance, and prognostic implications. Nephrol Dial
Transplant 2010;25(7):2066-2077.
Olmesartan for the delay of prevention of microalbuminuria
in patients type 2 diabetics. N Engl J Med 2011;364:907-917.
Nahas A, Bello A. Chronic kidney disease: the global challenge. Lancet 2005;365:331-340.
Foster MC, Hwang SJ, Larson MG, et al. The Framingham heart study. Am J Kidney Dis 2008;52(1):39-48.
Martínez CA, Martín de Francisco AL, Górriz JL, Alcázar LO. Estrategias en salud renal: un proyecto de la Sociedad Española de Nefrología. Nefrología 2009;29(3):185-192.
Bakris G, Williams M, Dworking L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;35:646-661.
Martín de Francisco AL, Aguilera L, Fuster V. Enfermedad cardiovascular, enfermedad renal y otras enfermedades crónicas. Es necesaria una intervención más temprana en la enfermedad renal crónica. Nefrología 2009;29(1):6-9.
Inserra F, De la Llave G, Dorado E, Castagna R, Marelli C. Estudio de factores de riesgo y enfermedad renal de familiares en primer grado de pacientes en diálisis. Nefrología Latinoamericana 2009;13(1):235,S372.
Amato D, Álvarez-Aguilar C, Castañeda LR, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int 2005;68(Suppl 97):S11-S17.
Méndez DA. Prevención del daño, manejo de la enfermedad renal crónica en el primer nivel de atención médica. Atem Fam 2010;17(3):74-78.
Rosas PM, Lara EA, Pastelín HG. Re-encuesta Nacional de Hipertensión Arterial (RENAHTHA): Consolidación Mexicana de los Factores de Riesgo Cardiovascular. Cohorte Nacional de Seguimiento. Arch Cardiol Mex 2005;75(1):96-111.
Saracho RR, Martínez FI, Amoroto E, et al. Prevalencia de enfermedad renal crónica (IRC) estadio 3 en la población general. Nefrología Latinoamericana 2009;13(1):168.S217.
Méndez-Durán A, Méndez-Bueno JF, Tapia-Yáñez T, Muñoz-Montes A, Aguilar-Sánchez L. Epidemiología de la insuficiencia renal crónica en México. Diálisis y Trasplante 2010;31(1):7-11.
Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. National Heart Lung and Blood Institute, 1998.
The seven report of the Joint National Committee Report on prevention, detection, evaluation and treatment of high blood pressure 2003. JAMA 2003;289:2560-2572.
Diagnosis and classification of diabetes mellitus. American Diabetes Association. Diabetes Care 2009;32(Suppl 1).
Diabetic Nephropathy. American Diabetes Association. Diabetes Care 2003;26(Suppl 1):S94.
KDOQI Guidelines 2000. National Kidney Foundation. Am J Kidney Dis 2002;39(Suppl 1):2.
Rossi MCE. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for awareness of renal and cardiovascular risk in diabetes) Study. Nephrol Dial Transplant 2008;23:1278-1284.
Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens 2001;3:99-102.
Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007;2:581-590.
Velázquez-Monroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelin-Hernández G. Grupo ENSA 2000. Hipertensión arterial en México: resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002;72(1):71-84.
Praga M, Hernández E, Morales E, et al. Clinical features and long term outcome of obesity associated focal segmental glomeruloesclerosis. Nephrol Dial Transplant 2001;16:1790-1798.
Chen J, Muntner P, Lee HL, et al. The metabolic syndrome and chronic kidney disease in US Adults. Ann Intern Med 2004;140:3.
Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HJ. Obesidad y daño a órgano blanco: el riñón. Int J Obes 2002;26(4):S21-24.
Aldhahi W, Hamdy O. Adipocinas, inflamación y endotelio en la diabetes. Curr Diab Rep 2004;3:22-27.
Iglesias P, Diez J. Adipose tissue in renal disease: clinical significance, and prognostic implications. Nephrol Dial Transplant 2010;25(7):2066-2077.
Olmesartan for the delay of prevention of microalbuminuria in patients type 2 diabetics. N Engl J Med 2011;364:907-917.
Full text